Plain-English translation of NCT06202066 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether (a chemotherapy pill) works better when combined with SurVaxM, an experimental vaccine designed to train your immune system to fight neuroendocrine cancer cells. Neuroendocrine cancers are rare tumors that can develop in the digestive system, pancreas, or lungs. This study is for patients whose cancer is progressing even after previous treatments.
Neuroendocrine cancers that keep growing despite standard treatment options have limited choices. Researchers believe that combining chemotherapy with a vaccine that helps the immune system recognize and attack cancer cells may help patients live longer without their cancer getting worse.
You likely qualify if…
You likely don't qualify if…
You would take the chemotherapy pill by mouth for 5 days every month for up to one year. You would also receive injections of the experimental vaccine under your skin every two weeks for the first 4 doses, with possible additional injections at months 6, 9, and 12 if your cancer improves. Throughout the study, you would have blood tests drawn and CT or MRI scans to monitor how your cancer is responding, with follow-up visits for 30 days after treatment ends.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States